Literature DB >> 23582413

In vivo mathematical modeling of tumor growth from imaging data: soon to come in the future?

F Cornelis1, O Saut, P Cumsille, D Lombardi, A Iollo, J Palussiere, T Colin.   

Abstract

The future challenges in oncology imaging are to assess the response to treatment even earlier. As an addition to functional imaging, mathematical modeling based on the imaging is an alternative, cross-disciplinary area of development. Modeling was developed in oncology not only in order to understand and predict tumor growth, but also to anticipate the effects of targeted and untargeted therapies. A very wide range of these models exist, involving many stages in the progression of tumors. Few models, however, have been proposed to reproduce in vivo tumor growth because of the complexity of the mechanisms involved. Morphological imaging combined with "spatial" models appears to perform well although functioning imaging could still provide further information on metabolism and the micro-architecture. The combination of imaging and modeling can resolve complex problems and describe many facets of tumor growth or response to treatment. It is now possible to consider its clinical use in the medium term. This review describes the basic principles of mathematical modeling and describes the advantages, limitations and future prospects for this in vivo approach based on imaging data.
Copyright © 2013 Éditions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23582413     DOI: 10.1016/j.diii.2013.03.001

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  7 in total

1.  Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors.

Authors:  Benjamin M Ellingson; Elizabeth R Gerstner; Andrew B Lassman; Caroline Chung; Howard Colman; Patricia E Cole; David Leung; Joshua E Allen; Manmeet S Ahluwalia; Jerrold Boxerman; Matthew Brown; Jonathan Goldin; Edjah Nduom; Islam Hassan; Mark R Gilbert; Ingo K Mellinghoff; Michael Weller; Susan Chang; David Arons; Clair Meehan; Wendy Selig; Kirk Tanner; W K Alfred Yung; Martin van den Bent; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2022-08-01       Impact factor: 13.029

Review 2.  Proposal of a hybrid approach for tumor progression and tumor-induced angiogenesis.

Authors:  Patricio Cumsille; Aníbal Coronel; Carlos Conca; Cristóbal Quiñinao; Carlos Escudero
Journal:  Theor Biol Med Model       Date:  2015-07-02       Impact factor: 2.432

3.  Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Authors:  Stephen K Horrigan
Journal:  Elife       Date:  2017-01-19       Impact factor: 8.140

4.  Replication study: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.

Authors:  Amirali Afshari; Ranjita Sengupta; Jeewon Kim; Vittorio Sebastiano; Archana Gupta; Young H Kim; Elizabeth Iorns; Rachel Tsui; Alexandria Denis; Nicole Perfito; Timothy M Errington; Elizabeth Iorns; Rachel Tsui; Alexandria Denis; Nicole Perfito; Timothy M Errington
Journal:  Elife       Date:  2018-12-11       Impact factor: 8.140

5.  A dynamic model of CT scans for quantifying doubling time of ground glass opacities using histogram analysis.

Authors:  József Z Farkas; Gary T Smith; Glenn F Webb
Journal:  Math Biosci Eng       Date:  2018-10-01       Impact factor: 2.080

6.  Classical mathematical models for description and prediction of experimental tumor growth.

Authors:  Sébastien Benzekry; Clare Lamont; Afshin Beheshti; Amanda Tracz; John M L Ebos; Lynn Hlatky; Philip Hahnfeldt
Journal:  PLoS Comput Biol       Date:  2014-08-28       Impact factor: 4.475

7.  Model-Supported Radiotherapy Personalization: In silico Test of Hyper- and Hypo-Fractionation Effects.

Authors:  Antonella Belfatto; Barbara Alicja Jereczek-Fossa; Guido Baroni; Pietro Cerveri
Journal:  Front Physiol       Date:  2018-10-15       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.